19 hrs ago
Arena Pharmaceuticals Sees Unusually High Options Volume
Arena Pharmaceuticals was the recipient of unusually large options trading activity on Monday.
Trending on the Topix Network
Fri Mar 07, 2014
Have Anti-Obesity Drug Companies Failed?
Orexigen may be a dark horse in the race due to its Contrave's mix of effectiveness and safety.
Arena Sees Growth Continue With Belviq
The script numbers for Arena Pharmaceuticals Belviq for the last week in February are in.
Wed Mar 05, 2014
Arena Pharmaceuticals EVP Unloads $175,250 in Stock
Arena Pharmaceuticals EVP Steven W. Spector unloaded 25,000 shares of Arena Pharmaceuticals stock on the open market in a transaction dated Tuesday, March 4th.
Tue Mar 04, 2014
Arena Pharmaceuticals Sees Large Decrease in Short Interest
Arena Pharmaceuticals was the recipient of a large decline in short interest in January.
Fri Feb 28, 2014
Arena Prescription Sales Up: Stops Stock Slide
Arena Pharmaceuticals reported earnings yesterday. Today the news and follow-through will be on prescription sales.
The Washington Post
U.S. Stock-Index Futures Fall as Economy Expands at Slower Pace
U.S. stock futures fell, after the Standard & Poor's 500 Index closed at a record yesterday, as data showed the world's largest economy expanded at a slower pace in the fourth quarter than previously estimated.
BRIEF-Arena Pharmaceuticals qtrly loss per share $0.11
Arena Pharmaceuticals Inc : * Provides corporate update and reports fourth quarter and full year 2013 financial results * Sees FY 2014 revenue of about $9 million from amortization of upfront payments from existing collaborations * Qtrly total revenues $6.5 million versus $1.9 million * Qtrly loss per share $0.11 * Q4 earnings per share view $0.02, ... (more)
Thu Feb 27, 2014
Arena Pharmaceuticals' CEO Discusses Q4 2013 Results - Earnings Call Transcript
Good day everyone, and welcome to Arena Pharmaceuticals' fourth quarter and full year 2013 update call.
NASDAQ Active Stock Watch List: Xilinx Inc. (NASDAQ:XLNX) and Arena...
Equity Profile Report expands its NASDAQ Active Stock Weekly Watch List adding Xilinx Inc. and Arena Pharmaceuticals, Inc. .
Arena Earnings On Tap
Arena Pharmaceuticals will announce earnings after the market closes at 5:00 PM Eastern time.
Tue Feb 25, 2014
The Motley Fool
Arena Pharmaceuticals, Inc. Earnings: What to Expect Thursday
With rival VIVUS having reported another round of disappointing sales of its competing drug Qsymia, investors have had to deal with skeptics arguing that medical professionals might choose not to embrace any new obesity drugs.
The Motley Fool
Another Big Failure for VIVUS, Inc.
The launch of its first-in-class obesity drug Qsymia was very highly anticipated among investors with the market potential being huge in this space, but sales just aren't panning out that way.
Mon Feb 24, 2014
NASDAQ Gainers Watch List: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)...
Equity Profile Report expands its NASDAQ Gainers Weekly Watch List adding Arena Pharmaceuticals, Inc. and Salix Pharmaceuticals Ltd. .
Fri Feb 21, 2014
Arena's Belviq Sales Continue Up As Others Decline
Arena Pharmaceuticals continues to see sales of its anti-obesity drug, Belviq, rise in 2014, albeit more modestly than some would have hoped.
Thu Feb 20, 2014
Arena Pharmaceuticals, Inc. To Provide Corporate Update And Report...
Please specify to the operator that you would like to join the "Arena Pharmaceuticals' Fourth Quarter and Full Year 2013 Financial Results Call."
The Motley Fool
Biotech Showdown: Arena Pharmaceuticals vs. VIVUS Inc.
As a result, shares of Arena are down 39% since Belviq was approved in the U.S., and VIVUS's shares have now fallen 74% since Qsymia gained approval.
Fri Feb 14, 2014
Arena Prescriptions Tracking With Expectations
Arena Pharmaceuticals' Belviq saw prescription numbers this week track with expectations.
Option Clips: Weight Watchers, Arena, and The Men's Wearhouse
Two equities generating buzz on StockTwits today are dieting concern Weight Watchers International, Inc. and drug maker Arena Pharmaceuticals, Inc. .
You Should Be Cautious Investing In Orexigen And Arena
In "Ode To Melancholy," the Romantic Poet John Keats portrayed melancholy's mutual relationships with joy for melancholy is the requisite for one to fully appreciate joy.